StockData
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc. (TSHA) shareholders

TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$4.00−0.06 (-1.48%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
91.9%
300M of 326M shares
Institutional holders
209
42 new, 22 sold out
Net institutional buying
34M
In Q2 2026
Insider trades, 12 months
0 buys · 12 sales
Net sold $6.66M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more
32,886,2429.90%13G (passive) amendmentJun 30, 2026
Rajeev Shah
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
27,662,4819.90%13G (passive) amendmentSep 30, 2025
Paul B Manning
Joint filing with The Paul B. Manning Revocable Trust dated May 10, 2000 (5.60%)
25,601,1119.80%13D (active) amendmentMay 30, 2025
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
25,345,9889.90%13G (passive) amendmentJun 30, 2025
Avoro Capital Advisors LLC
Joint filing with Behzad Aghazadeh (9.99%)
23,094,4449.99%13G (passive)Sep 30, 2024
Roderick Wong
Joint filing with RTW Investments, LP (7.00%)
20,689,0847.00%13G (passive) amendmentMar 31, 2026
RTW Investments, LP
Joint filing with Roderick Wong, M.D. (9.99%)
20,673,3079.99%13G (passive) amendmentMar 31, 2025
Ryan Wilder
Joint filing with Vestal Point Capital, LP (6.30%)
18,000,0006.30%13G (passive) amendmentMar 31, 2026
BlackRock, Inc.17,852,2916.50%13G (passive) amendmentDec 31, 2025
Morgan Stanley
Joint filing with Morgan Stanley Capital Services LLC (5.00%)
16,244,3395.10%13G (passive) amendmentJun 30, 2026
Abigail P. Johnson
Joint filing with FMR LLC (6.20%)
15,627,8226.20%13G (passive) amendmentJun 30, 2025
Vestal Point Capital, LP
Joint filing with Ryan Wilder (5.00%)
13,750,0005.00%13G (passive)Dec 31, 2025
Goldman Sachs & Co. LLC
Joint filing with The Goldman Sachs Group, Inc. (5.10%)
12,748,9685.10%13G (passive)Jun 26, 2025
Roderick Wong, M.D.
Joint filing with RTW Investments, LP (5.90%)
12,368,3345.90%13G (passive) amendmentDec 31, 2024
Octagon Capital Advisors LP
Joint filing with Octagon Investments Master Fund (5.10%), Ting Jia (5.10%)
10,450,0005.10%13G (passive)Dec 31, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of TSHAValueChange% of portfolio
Avoro Capital Advisors LLC23,888,8887.33%$162.68M+2,188,8881.46%
Ra Capital Management, L.P.23,555,6487.23%$160.41M–1.39%
Goldman Sachs Group Inc22,713,1186.97%$154.68M+343,4730.01%
BlackRock, Inc.20,691,9276.35%$140.91M+2,326,3190.00%
Vestal Point Capital, LP19,415,0005.96%$132.22M+1,415,0003.09%
Morgan Stanley16,487,4795.06%$112.28M−1,477,8920.01%
Rtw Investments, LP13,560,2584.16%$92.35M−119,9900.79%
FMR LLC13,336,4134.09%$90.82M−984,8420.00%
Vanguard Capital Management LLC12,478,5953.83%$84.98M+2,247,0930.00%
State Street Corp11,421,9203.51%$77.78M+212,8420.00%
Siren, L.L.C.9,846,5793.02%$67.06M+1,016,6661.36%
Octagon Capital Advisors LP9,693,2442.97%$66.01M+833,3335.93%
Geode Capital Management, LLC6,560,3942.01%$44.69M+1,028,4390.00%
Polar Capital Holdings Plc5,117,1331.57%$34.85M−537,2070.08%
Mpm Bioimpact LLC4,500,0001.38%$30.65MNew1.87%
D. E. Shaw & Co., Inc.4,398,6521.35%$29.95M−28,6490.01%
Baker Bros. Advisors LP4,004,7561.23%$27.27M–0.14%
Wellington Management Group Llp3,975,6051.22%$27.07M+3,349,2440.00%
Healthcare Of Ontario Pension Plan Trust Fund3,885,5011.19%$26.46M+1,002,2000.04%
Casdin Capital, LLC3,250,0001.00%$22.13M–1.11%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026209300M91.9%42 / 9941 / 2248M14M
Q1 2026191266M81.6%35 / 6949 / 3539M28M
Q4 2025195269M82.6%64 / 6246 / 2242M35M
Q3 2025155265M81.3%28 / 6135 / 2035M28M
Q2 2025150258M79.3%44 / 4834 / 2096M5M
Q1 2025127167M51.2%22 / 3931 / 2522M22M
Q4 2024131167M51.4%28 / 4528 / 1636M26M
Q3 2024120160M49.1%32 / 4516 / 1828M17M
Q2 2024107161M49.4%36 / 2822 / 3835M24M
Q1 2024109151M46.2%36 / 2927 / 1446M26M
Q4 202387130M40.0%32 / 3011 / 824M24M
Q3 202363130M39.9%35 / 146 / 11120M4M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

163 funds held TSHA in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of TSHAValue% of fundAs of
Vanguard Total Stock Market Index Fund9,138,0432.80%$62.23M0.00%Jun 30, 2026
iShares Russell 2000 ETF6,245,1341.92%$42.53M0.05%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF5,565,6381.71%$37.90M0.35%Jun 30, 2026
Fidelity Growth Company Fund4,176,1031.28%$24.51M0.02%May 31, 2026
Vanguard Extended Market Index Fund3,044,5540.93%$20.73M0.02%Jun 30, 2026
Fidelity Small Cap Index Fund2,622,7240.80%$15.37M0.05%Jul 31, 2026
iShares Russell 2000 Growth ETF2,213,2290.68%$15.07M0.10%Jun 30, 2026
iShares Biotechnology ETF1,687,4670.52%$11.49M0.13%Jun 30, 2026
Fidelity Extended Market Index Fund1,147,6080.35%$6.74M0.02%May 31, 2026
Vanguard Russell 2000 Index Fund1,134,5400.35%$6.66M0.04%May 31, 2026
Fidelity Growth Company K6 Fund1,098,1030.34%$6.45M0.02%May 31, 2026
Schwab U.S. Small-Cap ETF1,069,9550.33%$6.28M0.03%May 31, 2026
Select Biotechnology Portfolio940,4760.29%$5.52M0.10%May 31, 2026
Fidelity Enhanced Small Cap Core ETF810,8150.25%$5.52M0.10%Jun 30, 2026
Fidelity Series Growth Company Fund759,9200.23%$4.46M0.02%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Sukumar NagendranPresident and Head of R&D, Director936,4100.29%Jul 10, 2026
Sean P. NolanChief Executive Officer, Director4,443,8021.36%Jan 27, 2026
Kamran AlamCHIEF FINANCIAL OFFICER1,442,1310.44%Feb 6, 2026
Laura Sepp-LorenzinoDirector127,1780.04%Jun 2, 2026
Alison S. LongDirector127,1780.04%Jun 2, 2026
Phillip B. DonenbergDirector241,2890.07%Jun 2, 2026
John A. Stalfort IIIDirector2,060,8490.63%Jun 2, 2026
Paul B. Manning10% owner4,175,0371.28%Jun 3, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Sukumar Nagendran
President and Head of R&D, Director
Jul 10, 2026Sale(10b5-1 plan)−200,000$6.24$1.25M936,410
Phillip B. Donenberg
Director
Jun 1, 2026Award+21,335––241,289
John A. Stalfort III
Director
Jun 1, 2026Award+21,335––1,176,559
Laura Sepp-Lorenzino
Director
Jun 1, 2026Award+21,335––127,178
Alison S. Long
Director
Jun 1, 2026Award+21,335––127,178
Sukumar Nagendran
President and Head of R&D, Director
Apr 10, 2026Option exercise+19,021$1.71$32.53K1,336,410
Sukumar Nagendran
President and Head of R&D, Director
Apr 10, 2026Sale(10b5-1 plan)−200,000$4.46$892.00K1,136,410
Kamran Alam
CHIEF FINANCIAL OFFICER
Feb 4, 2026Sale−1,655$4.52$7.48K1,442,131
Kamran Alam
CHIEF FINANCIAL OFFICER
Jan 26, 2026Sale−23,849$4.61$109.94K1,443,786
Sean P. Nolan
Chief Executive Officer, Director
Jan 26, 2026Sale−41,312$4.61$190.45K2,908,257
Sukumar Nagendran
President and Head of R&D, Director
Jan 26, 2026Sale−26,918$4.61$124.09K1,317,389
Kamran Alam
CHIEF FINANCIAL OFFICER
Jan 23, 2026Sale−78,968$4.75$375.10K1,467,635
Sean P. Nolan
Chief Executive Officer, Director
Jan 23, 2026Sale−136,789$4.75$649.75K2,949,569
Sukumar Nagendran
President and Head of R&D, Director
Jan 23, 2026Sale−89,132$4.75$423.38K1,344,307
Sean P. Nolan
Chief Executive Officer, Director
Jan 12, 2026Award+1,008,000––3,086,358
Sukumar Nagendran
President and Head of R&D, Director
Jan 12, 2026Award+427,000––1,433,439
Sukumar Nagendran
President and Head of R&D, Director
Jan 12, 2026Sale(10b5-1 plan)−200,000$4.71$942.00K1,006,439
Sukumar Nagendran
President and Head of R&D, Director
Jan 12, 2026Option exercise+111,324$0.70$77.93K1,117,763
Sukumar Nagendran
President and Head of R&D, Director
Jan 12, 2026Option exercise+88,676$1.71$151.64K1,206,439
Kamran Alam
CHIEF FINANCIAL OFFICER
Jan 12, 2026Award+359,000––1,546,603
Sukumar Nagendran
President and Head of R&D, Director
Dec 1, 2025Option exercise+260,047$1.71$444.68K1,266,486
Sukumar Nagendran
President and Head of R&D, Director
Dec 1, 2025Sale−260,047$4.51$1.17M1,006,439
Sukumar Nagendran
President and Head of R&D, Director
Nov 28, 2025Option exercise+70,172$0.70$49.12K1,076,611
Sukumar Nagendran
President and Head of R&D, Director
Nov 28, 2025Option exercise+39,953$1.71$68.32K1,116,564
Sukumar Nagendran
President and Head of R&D, Director
Nov 28, 2025Sale−110,125$4.75$523.09K1,006,439
Sukumar Nagendran
President and Head of R&D, Director
Sep 10, 2025Sale(10b5-1 plan)−200,000$3.23$646.00K1,006,439
Sukumar Nagendran
President and Head of R&D, Director
Sep 10, 2025Option exercise+41,150$0.70$28.80K1,206,439
Kamran Alam
CHIEF FINANCIAL OFFICER
Aug 21, 2025Sale−54,491$2.85$155.30K1,187,603
Sukumar Nagendran
President and Head of R&D, Director
Aug 21, 2025Sale−57,054$2.85$162.60K1,165,289
Laura Sepp-Lorenzino
Director
Jun 2, 2025Award+56,623––105,843
Alison S. Long
Director
Jun 2, 2025Award+56,623––105,843
Phillip B. Donenberg
Director
Jun 2, 2025Award+56,623––219,954
John A. Stalfort III
Director
Jun 2, 2025Award+56,623––1,155,224
Paul B. Manning
10% owner
May 30, 2025Buy+750,000$2.75$2.06M2,841,704
Kamran Alam
CHIEF FINANCIAL OFFICER
Mar 11, 2025Tax withholding−29,843$1.69$50.43K1,242,094
Sukumar Nagendran
President and Head of R&D, Director
Jan 2, 2025Award+324,500––1,222,343
Kamran Alam
CHIEF FINANCIAL OFFICER
Jan 2, 2025Award+431,000––1,271,937
Sean P. Nolan
Chief Executive Officer, Director
Jan 2, 2025Award+892,500––2,078,358
Paul B. Manning
10% owner
Jun 27, 2024Buy+1,333,333$2.25$3.00M1,333,333
Alison S. Long
Director
May 29, 2024Award+49,220––49,220
Phillip B. Donenberg
Director
May 29, 2024Award+49,220––163,331
Laura Sepp-Lorenzino
Director
May 29, 2024Award+49,220––49,220
John A. Stalfort III
Director
May 29, 2024Award+49,220––1,098,601
Kamran Alam
CHIEF FINANCIAL OFFICER
Feb 2, 2024Tax withholding−1,288$1.51$1.94K840,937
Sukumar Nagendran
President and Head of R&D, Director
Jan 2, 2024Award+863,617––897,843
Sean P. Nolan
Chief Executive Officer, Director
Jan 2, 2024Award+1,184,688––1,185,858
Kamran Alam
Chief Financial Officer
Jan 2, 2024Award+590,413––842,225
Paul B. Manning
10% owner
Nov 17, 2023Buy+100,000$1.63$163.00K16,566,667
Kamran Alam
Chief Financial Officer
Aug 24, 2023Sale(10b5-1 plan)−33,000$2.33$76.89K258,042
Sean P. Nolan
Chief Executive Officer, Director
Aug 16, 2023Buy+444,444$0.90$400.00K1,535,545
Paul B. Manning
10% owner
Aug 16, 2023Buy+16,466,667$0.90$14.82M16,466,667
John A. Stalfort III
Director
Aug 16, 2023Gift+50,000––1,049,381
John A. Stalfort III
Director
Aug 16, 2023Buy+388,889$0.90$350.00K999,381
John A. Stalfort III
Director
Aug 16, 2023Buy+388,889$0.90$350.00K884,290
Phillip B. Donenberg
Director
Aug 16, 2023Buy+111,111$0.90$100.00K114,111
R.A. Session II
10% owner
Jul 13, 2023Sale−5,344$0.70$3.74K8,871,747
R.A. Session II
10% owner
Jul 12, 2023Sale−80,528$0.71$57.17K8,877,091
R.A. Session II
10% owner
Jun 23, 2023Sale−18,100$0.70$12.67K8,957,619
R.A. Session II
10% owner
Jun 22, 2023Sale−10,508$0.70$7.36K8,975,719
R.A. Session II
10% owner
Jun 21, 2023Sale−138,962$0.70$97.27K8,986,227

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
18.39%
53M shares short
Days to cover
14.8
At 4M shares a day
Change since last report
+4.3%
From 51M shares
Short volume, 20 days
63.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Taysha Gene Therapies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 505 shares on Sep 8, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Sukumar Nagendran
Officer
Jul 10, 2026200,000$1.30MJul 10, 2026Stock Option Grant
Sukumar Nagendran
Officer
Apr 10, 2026200,000$926.00KApr 10, 2026RSU Grant
Rumana Haque-Ahmed
Officer
Feb 27, 20262,405$10.99KFeb 27, 2026RSU Award
Kamran Alam
Officer
Feb 4, 20261,655$7.81KFeb 4, 2026RSU Award
Rumana Haque-Ahmed
Officer
Feb 4, 2026697$3.29KFeb 4, 2026RSU Award
Sean McAuliffe
Affiliate - Chief Business Officer
Feb 4, 2026914$4.31KFeb 4, 2026RSU Award
Fred Porter
Affiliate-Chief of Staff & Tech.Op.Officer
Feb 4, 2026889$4.20KFeb 4, 2026RSU Award
Emily McGinnis
Affiliate-Chief Pat. Adv. & Ext. Aff. Off.
Feb 4, 2026901$4.25KFeb 4, 2026RSU Award
Kamran Alam
Officer
Jan 23, 2026100,846$513.31KJan 23, 2026RSU Award
Sean McAuliffe
Affiliate - Chief Business Officer
Jan 23, 202646,064$234.47KJan 23, 2026RSU Award
Emily McGinnis
Affiliate-Chief Pat. Adv. & Ext. Aff. Off.
Jan 23, 202632,077$163.27KJan 23, 2026RSU Award
Rumana Haque-Ahmed
Officer
Jan 23, 202630,052$152.96KJan 23, 2026RSU Award
Sukumar Nagendran
Officer
Jan 23, 2026113,824$579.36KJan 23, 2026RSU Award
Sean P. Nolan
Officer, Director
Jan 23, 2026168,078$855.52KJan 23, 2026RSU Award
Fred Porter
Affiliate-Chief of Staff & Tech.Op.Officer
Jan 23, 202654,916$279.52KJan 23, 2026RSU Award

See a number that looks wrong?